BR112021024852A2 - Métodos de cultura de célula e composições para produção de anticorpo - Google Patents

Métodos de cultura de célula e composições para produção de anticorpo

Info

Publication number
BR112021024852A2
BR112021024852A2 BR112021024852A BR112021024852A BR112021024852A2 BR 112021024852 A2 BR112021024852 A2 BR 112021024852A2 BR 112021024852 A BR112021024852 A BR 112021024852A BR 112021024852 A BR112021024852 A BR 112021024852A BR 112021024852 A2 BR112021024852 A2 BR 112021024852A2
Authority
BR
Brazil
Prior art keywords
compositions
cell culture
culture methods
antibody production
antibody
Prior art date
Application number
BR112021024852A
Other languages
English (en)
Inventor
G Scarfo Edmund
Nandita Vishwanathan
Susan Lay Sokha
Kumar Gowtham Yogender
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112021024852A2 publication Critical patent/BR112021024852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos de cultura de célula e composições para produção de anticorpo. a presente invenção refere-se a métodos de cultura de célula para produzir um anticorpo anti-a4b7, por exemplo, vedolizumabe, bem como composições do mesmo.
BR112021024852A 2019-06-10 2020-06-10 Métodos de cultura de célula e composições para produção de anticorpo BR112021024852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859596P 2019-06-10 2019-06-10
US201962859563P 2019-06-10 2019-06-10
PCT/US2020/037080 WO2020252082A1 (en) 2019-06-10 2020-06-10 Cell culture methods and compositions for antibody production

Publications (1)

Publication Number Publication Date
BR112021024852A2 true BR112021024852A2 (pt) 2022-02-15

Family

ID=73780813

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024852A BR112021024852A2 (pt) 2019-06-10 2020-06-10 Métodos de cultura de célula e composições para produção de anticorpo

Country Status (14)

Country Link
US (1) US20220267448A1 (pt)
EP (1) EP3980068A4 (pt)
JP (1) JP2022536658A (pt)
KR (1) KR20220019725A (pt)
CN (4) CN117925709A (pt)
AU (1) AU2020291920A1 (pt)
BR (1) BR112021024852A2 (pt)
CA (1) CA3143246A1 (pt)
IL (1) IL288819A (pt)
MA (1) MA56130A (pt)
MX (1) MX2021015301A (pt)
PL (1) PL439808A1 (pt)
TW (1) TW202112819A (pt)
WO (1) WO2020252082A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023021532A1 (en) * 2021-08-20 2023-02-23 Dr. Reddy’S Laboratories Limited A process to produce a pharmaceutical composition
WO2024096506A1 (ko) * 2022-10-31 2024-05-10 삼성바이오에피스 주식회사 고농도 액체 배지 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0953041A4 (en) * 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2008232902B2 (en) * 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
ES2560470T3 (es) * 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
KR20210016479A (ko) * 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법

Also Published As

Publication number Publication date
CA3143246A1 (en) 2020-12-17
KR20220019725A (ko) 2022-02-17
WO2020252082A1 (en) 2020-12-17
PL439808A1 (pl) 2022-12-05
CN117925709A (zh) 2024-04-26
MX2021015301A (es) 2022-02-03
MA56130A (fr) 2022-04-13
EP3980068A1 (en) 2022-04-13
CN114206383A (zh) 2022-03-18
IL288819A (en) 2022-02-01
CN117925710A (zh) 2024-04-26
US20220267448A1 (en) 2022-08-25
CN117925711A (zh) 2024-04-26
JP2022536658A (ja) 2022-08-18
TW202112819A (zh) 2021-04-01
AU2020291920A1 (en) 2022-02-03
EP3980068A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
CO2019009365A2 (es) Anticuerpos anti-lag3
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
CR20180525A (es) Producción de ácido ribonucleico libre de células
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
BR112019018124A2 (pt) composições e métodos para imunooncologia
BR112018010605A2 (pt) nanoemulsões de bebidas produzidas por processamento de alto cisalhamento
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
CR20180445A (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
EA201500234A1 (ru) Способ получения бензоксазинонов
MX2018014764A (es) Metodo para producir acido 3-hidroxiadipico.
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
PH12020551663A1 (en) Genetic loci associated with increased fertility in maize
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
AR116719A1 (es) Microbiorreactor de flujo continuo
MX2018014769A (es) Metodo para producir acido a-hidromuconico.
BR112018006044A2 (pt) método de produção de mercaptanos por hidrogenólise enzimática de dissulfetos
BR112012022928A2 (pt) beta-hidroxialquilamidas, processo para sua produção, bem como seu uso
TR201905145T4 (tr) Diamin üreten mikroorganizma ve bunu kullanarak diamin üretimine yönelik yöntem.
BR112016006063A2 (pt) método para clarificação de uma colheita de cultura celular em bruto
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
BR112021020349A2 (pt) Peixe estéril
EA202090440A1 (ru) Улучшенное получение липидов путем ограничения по меньшей мере двух источников лимитирующих питательных веществ

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER.